Partnership and collaboration

A University of Queensland (UQ) researcher will play a key role with an international scientific team investigating the causes of Crohn’s disease as part of the Eastern Inflammatory Bowel Disease Gut Microbiota (ENIGMA) project.

Genes can help explain why some babies have a low birth weight, a major international study jointly led by The University of Queensland has found.

Patients’ genes could unlock urgently needed new treatments for severe sepsis, which kills three and a half times as many Australians as the road toll.

Researchers from the University of Queensland Diamantina Institute have led an international team of researchers as part of the largest ever genetic investigation into the causes of eczema.

Every year in Australia, more than 4000 people are diagnosed with Head and Neck Squamous Cell Carcinoma (HNSCC). In more than half of these patients, the disease is already advanced and their prognosis is poor.

New treatments are on the horizon for ankylosing spondylitis and two other debilitating conditions that affect up to three per cent of the global population – thanks to a research and development deal involving University of Queensland research.

Dr Andrew Brooks is part of an international team of scientists who have determined that unstructured parts of Class 1 cytokine receptors are able to interact with the inner membrane of cells.

Dr Roberta Mazzieri at the University of Queensland Diamantina Institute is working with cancer researchers in Italy to develop a non-toxic treatment for human breast cancer that delivers an anti-cancer molecule directly to a tumour.

A strategic partnership between The University of Queensland and global pharmaceutical company LEO Pharma will investigate the genetic causes of squamous cell carcinoma, the world’s second most common skin cancer.

Scientists from The University of Queensland’s Diamantina Institute (UQDI) and Institute for Molecular Bioscience (IMB) have identified three new genes behind Jeune Syndrome.